文献速递泌尿生殖与妇科肿瘤放疗

活检组织Gleason 4阳性绝对百分比(APP4)对中危前列腺癌高剂量率近距离放疗联合外照射后疾病控制的预测作用

Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer.
PubMed 文献 · Radiother Oncol · 2019-03-27

该回顾性研究纳入411例中危前列腺癌患者,计算活检组织中Gleason 4阳性组织的绝对百分比(APP4),并进行竞争风险分析。中位随访5.2年,APP4 optimal cutpoint分别为>3.3%、>6.6%和>17.5%时,分别与生化失败、因生化失败使用ADT和转移风险增加相关,但需外部验证。

要点

  • APP4>3.3%与生化失败风险增加相关(HR 2.3,p=0.031)。
  • APP4>6.6%与因生化失败使用ADT风险增加相关(HR 3.7,p=0.009)。
  • APP4>17.5%与转移风险显著增加相关(HR 25.7,p<0.001)。

核心结论

  • APP4 cutpoint>3.3%、>6.6%和>17.5%分别与生化失败、因生化失败使用ADT和发生转移的风险增加强烈相关。

研究设计与样本

  • 回顾性纳入411例中危前列腺癌患者,基于活检报告计算APP4,采用多变量竞争风险分析预测生化失败、因生化失败使用ADT和转移。

主要发现

  • 中位随访5.2年(IQR 2.9-6.6),中位基线PSA 7.3 ng/mL(IQR 5.3-9.8),234例(56.9%)为T1期,177例(43.1%)为T2期。
  • 中位APP4为2.00%(IQR 0.75-7.50%),38例(9.3%)发生生化失败,17例(4.1%)因生化失败使用ADT,8例(2.0%)发生转移。
  • 预测生化失败的APP4 optimal cutpoint为>3.3%(AUC 0.66),预测因生化失败使用ADT的cutpoint为>6.6%(AUC 0.72),预测转移的cutpoint为>17.5%(AUC 0.86)。

关键数值与推荐

  • APP4>3.3%为预测生化失败的optimal cutpoint(AUC 0.66)。
  • APP4>6.6%为预测因生化失败使用ADT的cutpoint(AUC 0.72)。
  • APP4>17.5%为预测转移的cutpoint(AUC 0.86)。

临床怎么用

  • 在中危前列腺癌接受高剂量率近距离放疗联合外照射前,可计算APP4以辅助风险分层,但结论需外部验证。

局限性

  • 回顾性研究设计,APP4 cutpoint需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To identify if, in intermediate risk prostate cancer (IR-PCa), the absolute percentage of biopsied tissue positive for pattern 4 disease (APP4) may be a predictor of outcome. MATERIALS AND METHODS: 411 patients with IR-PCa were retrospectively reviewed. APP4 was calculated based on biopsy reports. Multivariable competing risk analysis was then performed on optimized APP4 cutpoints to predict for biochemical failure (BF), androgen deprivation use for BF (ADT-BF) and development of metastases (MD). RESULTS: Median follow-up for the cohort was 5.2 (Inter Quartile Range: 2.9-6.6) years. Median baseline PSA was 7.3 (5.3-9.8) ng/mL. 234 (56.9%) patients had T1 and 177 (43.1%) had T2 disease. Median APP4 was 2.00 (0.75-7.50)%. 38 (9.3%) patients experienced BF. The optimal cutpoint of APP4 for BF was >3.3% with an area under the curve (AUC) of 0.66. 17 (4.1%) received ADT-BF. The ADT-BF cutpoint was >6.6% with an AUC of 0.72. Eight (2.0%) developed MD. The MD cutpoint was >17.5% with an AUC of 0.86. Using APP4 >3.3 vs ≤ 3.3, log-transformed baseline PSA ln(PSA) (HR 2.5, 1.1-6.1; p = 0.037) and APP4 (HR 2.3, 1.1-4.7; p = 0.031) predicted for BF. Using APP4 >6.6 vs ≤ 6.6, ln(PSA) (HR 4.2, 1.4-12.4; p = 0.010) and APP4 (HR 3.7, 1.4-10.0; p = 0.009) were predictive of ADT-BF. APP4 >17.5 vs ≤ 17.5 alone was predictive of MD (HR 25.7, 4.9-135.3; p < 0.001). CONCLUSION: APP4 cutpoints of >3.3%, >6.6% and >17.5% were strongly associated with increased risk of BF, ADT-BF and developing MD respectively. These findings may inform future practice when treating IR-PCa but require external validation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Martell K, Mendez LC, Chung H, et al. Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer. Radiother Oncol. 2019. PMID: 31015164. doi:10.1016/j.radonc.2019.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。